Microbiota and Immune Regulation in Lung Transplantation

Abstract Purpose of the Review The lung and gut microbiomes have been associated with many important patient-centered outcomes in respiratory diseases, and these have been further associated with pulmonary immunity. Lung transplant patients are necessarily unique with regards to their microbiome characteristics and their immune responses. The goal of this review is to summarize the emerging literature relevant to of bidirectional relationship of the microbiome and pulmonary immunity, with a focus on data relevant to lung transplant recipients. Recent Findings Lung transplant patients tend to have increased lung bacterial burden and shifts in microbial community composition relative to healthy controls. These lung microbiome changes are linked to important post-transplant outcomes, including primary graft dysfunction, acute rejection, and chronic lung allograft dysfunction. Furthermore, these lung microbiome characteristics—especially having an increased lung bacterial burden or communities dominated by “pathogenic” taxa are associated with a pro-inflammatory pulmonary immune signals in lung transplant patients, despite their concurrent use of immunosuppression. The gut microbiome, through systemic pathways such as short-chain fatty acid (SCFA) production, also appears to influence pulmonary immunity in non-transplant patients, although its role in lung transplant recipients remains underexplored. Summary The lung microbiome remains an important factor in pulmonary immunity after lung transplantation, and the gut microbiome has been implicated as further impacting pulmonary and systemic immunity in non-transplant population. Microbiome-targeted interventions show promise—especially in selected populations—but have not yet been linked with improved patient-centered outcomes. Further research which incorporates adequate clinical context is needed to disentangle which microbiome features and immune signals might be harnessed or targeted to optimize post-transplant care and prolong allograft survival.

Authors

Institutions

Publication Details

Journal
Current Transplantation Reports
Published
2026-02-12
DOI
https://doi.org/10.1007/s40472-026-00502-1
Primary Topic
Transplantation: Methods and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microbiota and Immune Regulation in Lung Transplantation

M.P. Combs
Current Transplantation Reports
Transplantation: Methods and Outcomes
article

Microbiota and Immune Regulation in Lung Transplantation

M.P. Combs
article en

Abstract

Abstract Purpose of the Review The lung and gut microbiomes have been associated with many important patient-centered outcomes in respiratory diseases, and these have been further associated with pulmonary immunity. Lung transplant patients are necessarily unique with regards to their microbiome characteristics and their immune responses. The goal of this review is to summarize the emerging literature relevant to of bidirectional relationship of the microbiome and pulmonary immunity, with a focus on data relevant to lung transplant recipients. Recent Findings Lung transplant patients tend to have increased lung bacterial burden and shifts in microbial community composition relative to healthy controls. These lung microbiome changes are linked to important post-transplant outcomes, including primary graft dysfunction, acute rejection, and chronic lung allograft dysfunction. Furthermore, these lung microbiome characteristics—especially having an increased lung bacterial burden or communities dominated by “pathogenic” taxa are associated with a pro-inflammatory pulmonary immune signals in lung transplant patients, despite their concurrent use of immunosuppression. The gut microbiome, through systemic pathways such as short-chain fatty acid (SCFA) production, also appears to influence pulmonary immunity in non-transplant patients, although its role in lung transplant recipients remains underexplored. Summary The lung microbiome remains an important factor in pulmonary immunity after lung transplantation, and the gut microbiome has been implicated as further impacting pulmonary and systemic immunity in non-transplant population. Microbiome-targeted interventions show promise—especially in selected populations—but have not yet been linked with improved patient-centered outcomes. Further research which incorporates adequate clinical context is needed to disentangle which microbiome features and immune signals might be harnessed or targeted to optimize post-transplant care and prolong allograft survival.

Current Transplantation ReportsVol. 13(1)
Vanderbilt University Medical Center (US)
Openalex Percentile: Top 59%
Transplantation: Methods and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.